BFH772 (VEGFR2 inhibitor): Technical Application and Protocol Guide

What This Product Solves

BFH772 is a potent and selective small molecule inhibitor targeting the VEGFR2 kinase, a pivotal receptor in angiogenic signaling pathways. By specifically disrupting VEGFR2-mediated signaling, it enables researchers to modulate angiogenesis in preclinical settings with minimal off-target effects. This makes BFH772 particularly suitable for studies focused on tumor angiogenesis, VEGFR2 pathway mapping, and the assessment of anti-angiogenic agents in animal models. Its high selectivity—demonstrated by a 3 nM IC50 for VEGFR2 and markedly reduced activity against related kinases—minimizes confounding cross-reactivity in experiments where pathway specificity is required (source: product_spec).

Researchers should be aware that BFH772 is not appropriate for workflows that require water-soluble compounds or for studies aiming to inhibit multiple kinase families simultaneously. Its solubility and selectivity profiles define clear experimental boundaries.

For further workflow-specific recommendations, see BFH772 (VEGFR2 inhibitor): Protocols & Practical Use in Research, which offers additional procedural detail on integrating this compound into angiogenesis research pipelines.

Protocol Parameters

• assay | IC50 = 3 nM (VEGFR2) | Use in targeted VEGFR2 signaling pathway inhibition | Enables precise suppression of VEGFR2-mediated angiogenesis with minimal off-target effects | product_spec
• assay | Solubility ≥53.4 mg/mL in DMSO; ≥15.33 mg/mL in ethanol | Applicable for in vitro and in vivo studies requiring organic solvent-based delivery | Ensures preparation of concentrated stock solutions for dosing flexibility; not suitable for aqueous systems | product_spec
• assay | Storage at -20°C; avoid long-term storage of solutions | Best for workflows with short-term solution use and reliable cold storage | Maintains compound integrity and prevents degradation; solutions are unstable over time | product_spec
• assay | Purity >96% | Suitable for applications demanding high-purity small molecules | Minimizes experimental variability from impurities; QC data provided by manufacturer | product_spec
• assay | Oral administration validated in animal tumor models | Recommended for in vivo studies of tumor angiogenesis or growth suppression | Supports translational research in anti-angiogenic therapy development | product_spec

Workflow Setup and QC Checklist

• Compound Handling: Prepare all BFH772 stock solutions in DMSO or ethanol at concentrations up to manufacturer-stated solubility limits. Avoid water as a solvent due to insolubility (source: product_spec).
• Aliquoting: Dispense single-use aliquots to minimize freeze-thaw cycles, which may compromise compound stability. Store aliquots at -20°C and avoid repeated temperature changes.
• Solution Use: Prepare working dilutions immediately prior to use. Discard any unused solution rather than storing for future applications, as long-term stability data for solutions are not supported (source: product_spec).
• Assay Controls: Include DMSO or ethanol vehicle controls in parallel to BFH772 treatments to account for solvent effects in both cell-based and animal studies.
• Documentation: Retain and review the certificate of analysis and safety data sheet supplied with each lot for reference on purity and handling precautions.
• Quality Verification: Confirm batch purity (>96%) and verify molecular weight (439.39 g/mol) as specified by the supplier prior to experimental deployment.

Common Failure Modes and Fixes

• Incomplete Dissolution: If BFH772 does not dissolve fully in DMSO or ethanol, gently warm the solution (e.g., room temperature or 37°C water bath) and vortex. Avoid excessive heating, which may degrade the compound.
• Loss of Activity: Reduced biological efficacy may result from using aged or repeatedly thawed solutions. Always prepare fresh working stocks and avoid storing diluted solutions.
• Precipitation in Media: When diluting BFH772 into aqueous buffers or cell culture media, add the compound slowly and with continuous mixing to prevent precipitation. Maintain final DMSO/ethanol concentrations at or below cytotoxic thresholds for your system.
• Unexpected Off-Target Effects: Despite high selectivity, validate experimental specificity using appropriate controls. Avoid using BFH772 where broad-spectrum kinase inhibition is required (related article).
• Animal Model Variability: For in vivo oral administration, ensure formulation compatibility and monitor for compound precipitation or instability over time.

Scope and Limitations

BFH772 is formulated for research use in the targeted inhibition of VEGFR2-mediated angiogenesis. Its solubility profile restricts use to DMSO- or ethanol-based systems, precluding applications requiring aqueous solubility. The compound's selectivity profile is advantageous for studies focusing on VEGFR2, but it is not suitable for experiments necessitating broad kinase inhibition or for use in workflows incompatible with organic solvents (source: product_spec).

Further, BFH772 is not intended for use in clinical diagnosis or therapy outside controlled research environments. Long-term storage of solutions is not recommended, as stability data support only short-term use. Researchers should consult the latest certificates of analysis and safety data sheets for lot-specific handling guidance.

Conclusion

BFH772 offers a robust, selective approach to inhibiting the VEGFR2 signaling pathway in angiogenesis and tumor growth research. Adhering to the specified solubility, storage, and quality control practices will maximize reproducibility and data integrity. For comprehensive details and procedural best practices, refer to the BFH772 (VEGFR2 inhibitor) product page and internal protocol resources.